See more : Shindengen Electric Manufacturing Co.,Ltd. (6844.T) Income Statement Analysis – Financial Results
Complete financial analysis of Elevation Oncology, Inc. (ELEV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevation Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Divide Drives Inc. (DVDR) Income Statement Analysis – Financial Results
- TELUS Corporation (T.TO) Income Statement Analysis – Financial Results
- LPP SA (LPP.WA) Income Statement Analysis – Financial Results
- Konica Minolta, Inc. (KNCAY) Income Statement Analysis – Financial Results
- Anhui Genuine New Materials Co.,Ltd. (603429.SS) Income Statement Analysis – Financial Results
Elevation Oncology, Inc. (ELEV)
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.00K | 27.00K | 18.00K | 15.00K | 0.00 |
| Gross Profit | -39.00K | -27.00K | -18.00K | -15.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.43M | 78.72M | 23.60M | 15.48M | 5.34M |
| General & Administrative | 14.90M | 15.83M | 8.45M | 1.80M | 816.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 543.18K |
| SG&A | 14.90M | 15.83M | 8.45M | 1.80M | 544.00K |
| Other Expenses | 5.11M | -506.00K | 7.00K | 11.00K | 0.00 |
| Operating Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Cost & Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Interest Income | 3.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 479.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 39.00K | 27.00K | 18.00K | 15.00K | 3.57M |
| EBITDA | -41.47M | -94.52M | -32.03M | -17.25M | -5.88M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.45M | -94.55M | -32.05M | -17.28M | -5.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -229.00K | -506.00K | 7.00K | 11.00K | 0.00 |
| Income Before Tax | -45.67M | -95.06M | -32.04M | -17.27M | -5.88M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 30.00K | 25.00K | -218.56K | -191.30K | -8.82K |
| Net Income | -45.70M | -95.08M | -32.04M | -17.27M | -5.88M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| EPS Diluted | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| Weighted Avg Shares Out | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
| Weighted Avg Shares Out (Dil) | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON , March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused...
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D.
BOSTON , March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs,...
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
PHILADELPHIA , Feb. 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Elevation Oncology, Inc. (NYSE: ELEV) on behalf of the company's investors. The investigation seeks to determine whether Elevation Oncology and/or the company's officers and directors...
Elevation Oncology to Participate in Upcoming Investor Conferences
BOSTON , Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs,...
3 Stock Winners That Are Up 400% or More in 2024
The stock market has seen a remarkable surge in recent months, climbing 21% since the end of October. Rallies as strong as this one tend to yield several stock winners, which in this case are primarily GenAI-focused companies.
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
-- On track to provide update from ongoing Phase 1 clinical trial in mid-2024; additional data expected in 1H 2025 -- BOSTON , Feb. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the...
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
BOSTON , Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs,...
Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones
-- Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 -- -- Expanding EO-3021 Clinical Development Program to Include Combination Strategy -- -- Announcing HER3-targeting ADC as Second Pipeline Program; Development Candidate Nomination in 2024-- -- Entering...
Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference
BOSTON , Nov. 22, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs,...
Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements
-- Enrollment is ongoing in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2; preliminary safety and anti-tumor activity data expected in 1H 2025 -- BOSTON , Nov. 2, 2023 /PRNewswire/...
Source: https://incomestatements.info
Category: Stock Reports